The U.S. Food and Drug Administration staff continue to conduct critical work to protect the public health during the COVID-19 pandemic. For example, the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) have played key roles in supporting FDA’s work to respond to the COVID-19 public health emergency by contributing to a special emergency program for possible coronavirus therapies, the Coronavirus Treatment Acceleration Program (CTAP) . This program uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful and supporting clinical trials.
Today, FDA posted an updated Coronavirus Treatment Acceleration Program (CTAP) webpage. The newly revised webpage has key materials to provide information about CTAP’s purpose, strategy and operations. Specifically, this update includes posting a dashboard showing crucial statistics related to the development of potential COVID-19 therapeutics. We expect to update these statistics on a monthly basis. We’ve also included key guidances and webpage links for therapeutic developers, researchers, patients and consumers. For example, FDA’s latest Voices article on CTAP is posted on the revised web page to give more context to CTAP’s efforts. If you have questions related to CTAP please see our webpage for contact information or email druginfo@fda.hhs.gov. |
|
|
|
.png)
No hay comentarios:
Publicar un comentario